Pirfenidone prevents lipotoxicity-induced insulin resistance and steatohepatitis by regulating immune cell accumulation and macrophage polarization in the livers of mice. Additionally, pirfenidone suppresses hepatic fibrosis by inhibiting activation of stellate cells and TGF-β1 expression; and reverses insulin resistance, hepatic inflammation, and fibrosis in mice with pre-existing nonalcoholic steatohepatitis.
- Guanliang Chen
- Yinhua Ni
- Tsuguhito Ota
